Abstract:Objective: The current guidelines and canonical norms of diagnosis or treatment for Post-traumatic stress disorder (PTSD) with sleep disorder are still conflicting and have not yet reached a consensus. This study aimed to unravel the most effective countermeasures between two categories (psychotherapy and pharmacotherapy) put forward by the National Institute for Health and Clinical Excellence (NICE) and World Federation of Societies of Biological Psychiatry (WFSBP) respectively to treat PTSD individuals co-exist with sleep disorders. Methods: Four databases, including PubMed, EMBASE, Cochrane Library, and APA PsyNet, were searched from inception to February 02, 2023. Results: Twenty articles with 24 Randomized controlled trials (RCTs) and a total number of 1,647 participants were included. As demonstrated in the network meta-analysis comparison results, CBT-I (standardized mean differences (SMD) = -1.51,95% confidence interval (CI):-2.55 to -0.47), CBT-I plus IRT (SMD = -1.71, 95%CI:-3.39, -0.03), prazosin (SMD = -0.87,95%CI:-1.59 to -0.16) and hydroxyzine (SMD = -1.06, 95%CI: -1.94 to -0.19) significantly reduced PTSD symptoms compared with placebo. In contrast to placebo, CBT-I (SMD = -5.61,95%CI:-8.82 to -2.40) significantly improved sleep quality. For nightmare severity, IRT (SMD =-0.65, 95%CI:-1.00 to -0.31), prazosin (SMD = -1.20,95%CI:-1.72 to -0.67) and hydroxyzine (SMD = -0.98,95%CI:-1.58 to -0.37) significantly reduced nightmare severity in comparison with placebo. Conclusions: This study suggested that under most circumstances, psychotherapy namely CBT-I had a favorable profile, but pharmacotherapy with prazosin was effective in managing nightmare severity. The sole avail of CBT-I was recommended to improving sleep quality while CBT-I and CBT-I plus IRT showed excellent management of PTSD symptom severity. Exposure to CBT-I isrecommended for depression. The relevant clinical guidelines for the management of individuals with PTSD and sleep disorders may regard this as a reference. Prospero: CRD42023415240.

Pharmakologische Behandlung der Posttraumatischen Belastungsstörung

Neuromodulation Strategies in Post-Traumatic Stress Disorder: From Preclinical Models to Clinical Applications

Treatment-refractory posttraumatic stress disorder (TRPTSD): a review and framework for the future

Pharmacotherapy for posttraumatic stress disorder: Review with clinical applications

Pharmacotherapy for sleep disturbances in post-traumatic stress disorder (PTSD): a network meta-analysis

New approaches to combining pharmacotherapy and psychotherapy for posttraumatic stress disorder

Klinisches Management der therapieresistenten Depression

Evidenzbasierte Psychotherapie posttraumatischer Belastungsstörungen – ein Update

Pharmacotherapy for posttraumatic stress disorder: empirical review and clinical recommendations

Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis

An evidence-based approach to psychopharmacology for posttraumatic stress disorder (PTSD) - 2022 update

Psychotherapeutic and pharmacological agents for post-traumatic stress disorder with sleep disorder: network meta-analysis

Dialektisch behaviorale Therapie für komplexe posttraumatische Belastungsstörung (DBT-PTBS): ein evidenzbasiertes störungsspezfisches Behandlungsprogramm

Post-Traumatic Stress Disorder: Administration, Clinical and Pharmacological, Organizational and Legal, Pharmaceutical Management, Recent Case Studies

Evidenced-Based Treatment of Posttraumatic Stress Disorder: An Updated Review of Validated Psychotherapeutic and Pharmacological Approaches

Pharmacological Management of Nightmares Associated with Posttraumatic Stress Disorder

Proposing an algorithm for the pharmacological management of posttraumatic stress disorder

Post-traumatic Stress Disorder: A Narrative Review of Pharmacological and Psychotherapeutic Interventions

Clinical outcomes of recommended active pharmacotherapy agents from NICE guideline for post-traumatic stress disorder: Network meta-analysis